Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 38
States / cities: Little Rock, Arkansas • Los Angeles, California • Pasadena, California + 31 more

Conditions: Type 2 Diabetes
Interventions: Liraglutide, Metformin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 25 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
Interventions: CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo; Drug
Lead sponsor: Cingulate Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina

Conditions: Pain
Interventions: Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 3
States / cities: Tucson, Arizona • Naples, Florida • Kingston, Rhode Island

Conditions: EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Interventions: Olaparib, Durvalumab, EKG, Tumor biopsy, CT chest, abdomen and pelvis, MRI chest, abdomen and pelvis; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: emtricitabine 200 mg/tenofovir alafenamide 25mg; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 59 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: PTSD
Interventions: Riluzole, Placebo (for Riluzole); Drug
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Bethesda, Maryland • Syracuse, New York

Conditions: Bacterial Infections
Interventions: Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Little Rock, Arkansas • Long Beach, California • Orange, California + 6 more

Conditions: Sexually Transmitted Infections, Gay, Pre Exposure Prophylaxis
Interventions: Quantitative survey, HIV and STI testing, Qualitative Assessment; Behavioral · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 675 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: San Diego, California • Atlanta, Georgia • Chicago, Illinois

Conditions: Chronic Cough
Interventions: Placebo, Gefapixant 15 mg BID, Gefapixant 45 mg BID; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 34
States / cities: Peoria, Arizona • Phoenix, Arizona • Tempe, Arizona + 31 more

Conditions: Chronic Hepatitis C
Interventions: Sofosbuvir, RBV, PEG; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 55
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 43 more

Conditions: Breast Cancer
Interventions: Letrozole; Drug
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 4,884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis
Interventions: VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 25
States / cities: New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more

Conditions: Diabetic Neuropathy
Interventions: DA-9801 300mg, DA-9801 600mg, DA-9801 900mg, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 14
States / cities: Lakewood, California • Walnut Creek, California • Milford, Connecticut + 10 more

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 49
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more

Conditions: Chronic Kidney Disease
Interventions: Sodium Bicarbonate, Placebo, Exercise Training, Control to Exercise (Stretching); Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: HIV Infections
Interventions: Atazanavir+Ritonavir+Tenofovir, Atazanavir+Ritonavir+Tenofovir+Famotidine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Hamilton, New Jersey

Conditions: Prehypertension, Hypertension
Interventions: Nebivolol, Metoprolol, Placebo, Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min), FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min), FBF response to Acetylcholine, FBF response to Sodium Nitroprusside, FBF response to BQ-123+BQ-788+ACh; Drug · Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 45 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: CMV Disease
Interventions: Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more

Conditions: Migraine
Interventions: 91-day Levonorgestrel Oral Contraceptive, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: La Mesa, California • San Diego, California • San Francisco, California + 18 more

Conditions: Cystic Fibrosis, Advanced Lung Disease
Interventions: Lumacaftor, Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Denver, Colorado • Tampa, Florida • Chicago, Illinois + 3 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral, GSK1265744 400 mg (200 nm), GSK1265744 400 mg (1 micro m), GSK1265744 400 mg (5 micro m); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Solid Tumor
Interventions: Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus; Drug
Lead sponsor: Miller Children's & Women's Hospital Long Beach; Other
Eligibility: 12 Months to 31 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 2
States / cities: Long Beach, California • Orange, California

Conditions: Prostatic Neoplasms
Interventions: Docetaxel, Leuprolide, Bicalutamide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

The Cellular Pharmacology of F-TAF in Dried Blood Spots

Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Study of DA-9801 to Treat Diabetic Neuropathy

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Sympatholysis in Chronic Kidney Disease

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

Nebivolol and the Endothelin (ET)-1 System

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)